基本信息
浏览量:89
职业迁徙
个人简介
Pediatric cancer affects more than 10,000 children, from birth to 14 years of age, every year. It remains a leading cause of death from disease among children, reports the National Cancer Institute. As such, researchers need to continue pursuing experiments and therapies to save children’s lives from pediatric cancer.
My research areas include cancer biology, tumor angiogenesis, drug development, DNA damage repair, structural biology, phosphatases, retinal disease and pulmonary arterial hypertension.
Our lab is interested in elucidating molecular mechanisms that promote the proliferation of cells under conditions of stress, as seen in diseases such as cancer, retinopathy of prematurity and pulmonary arterial hypertension (PAH). We then manipulate this knowledge to develop innovative therapeutic approaches. My colleagues and I utilize structure-based drug design, experimental high-throughput drug screens and virtual screening to find the right drug types and test them in pre-clinical animal models.
For more than 20 years, my lab team members and I have been studying molecular mechanisms that drive disease processes with a specific interest in the ability of disease-associated cells to survive conditions of hypoxic stress.
One notable discovery from my lab in the mid-2000s was finding that the Eyes Absent (EYA) protein, which is part of the signaling cascade, is the founding member of a new mechanistic class of protein tyrosine phosphatases. We have since linked this activity of the EYA proteins to angiogenesis, cell migration and cells' endurance under oxidative stress. We have since identified small molecule inhibitors of the EYA protein tyrosine phosphatases (PTP) activity.
Other notable discoveries from my lab include:
Demonstrating that the EYA PTP activity contributes to both developmental and pathological angiogenesis
In vivo validation of an EYA-PTP inhibitor as an anti-angiogenic agent in a tumor model
In vivo validation of an EYA-PTP inhibitor as a possible therapeutic factor when treating retinopathy of prematurity as well as in treating pulmonary arterial hypertension
In addition, I have received numerous recognitions and awards during my career, including:
Faculty Achievement Award in Education, Cincinnati Children’s Hospital Medical Center (2017)
National Cancer Center Postdoctoral Fellowship (1991-1993)
Dean’s Recognition Citation for Excellence in Medical Education, NYU (1999)
Whitehead Presidential Award for Junior Faculty, NYU (1995)
Bombay University Certificate of Merit (1982)
National Science Talent Search Scholarship (1979)
I have more than 30 years of experience in the study of cancer biology, the molecular basis of disease and structure-aided drug design. I joined the team at Cincinnati Children’s Hospital Medical Center in 2002. I’m also the founding director of the Graduate Program in Biomedical Research Technologies at Cincinnati Children’s Hospital Medical Center.
Clinical Interests
Pre-clinical validation of anti-angiogenic agents for use in the treatment of retinopathies, cancer and pulmonary disease.
Research Interests
Molecular mechanisms involved in normal development and in disease states using in vitro (cellular and solution biochemistry and structural biology) and in vivo (mouse models) strategies; developing novel therapeutic strategies via structure-aided drug design coupled with in vitro validation and in vivo pre-clinical studies.
Academic Affiliation
Professor, UC Department of Pediatrics
Research Divisions
Developmental Biology
My research areas include cancer biology, tumor angiogenesis, drug development, DNA damage repair, structural biology, phosphatases, retinal disease and pulmonary arterial hypertension.
Our lab is interested in elucidating molecular mechanisms that promote the proliferation of cells under conditions of stress, as seen in diseases such as cancer, retinopathy of prematurity and pulmonary arterial hypertension (PAH). We then manipulate this knowledge to develop innovative therapeutic approaches. My colleagues and I utilize structure-based drug design, experimental high-throughput drug screens and virtual screening to find the right drug types and test them in pre-clinical animal models.
For more than 20 years, my lab team members and I have been studying molecular mechanisms that drive disease processes with a specific interest in the ability of disease-associated cells to survive conditions of hypoxic stress.
One notable discovery from my lab in the mid-2000s was finding that the Eyes Absent (EYA) protein, which is part of the signaling cascade, is the founding member of a new mechanistic class of protein tyrosine phosphatases. We have since linked this activity of the EYA proteins to angiogenesis, cell migration and cells' endurance under oxidative stress. We have since identified small molecule inhibitors of the EYA protein tyrosine phosphatases (PTP) activity.
Other notable discoveries from my lab include:
Demonstrating that the EYA PTP activity contributes to both developmental and pathological angiogenesis
In vivo validation of an EYA-PTP inhibitor as an anti-angiogenic agent in a tumor model
In vivo validation of an EYA-PTP inhibitor as a possible therapeutic factor when treating retinopathy of prematurity as well as in treating pulmonary arterial hypertension
In addition, I have received numerous recognitions and awards during my career, including:
Faculty Achievement Award in Education, Cincinnati Children’s Hospital Medical Center (2017)
National Cancer Center Postdoctoral Fellowship (1991-1993)
Dean’s Recognition Citation for Excellence in Medical Education, NYU (1999)
Whitehead Presidential Award for Junior Faculty, NYU (1995)
Bombay University Certificate of Merit (1982)
National Science Talent Search Scholarship (1979)
I have more than 30 years of experience in the study of cancer biology, the molecular basis of disease and structure-aided drug design. I joined the team at Cincinnati Children’s Hospital Medical Center in 2002. I’m also the founding director of the Graduate Program in Biomedical Research Technologies at Cincinnati Children’s Hospital Medical Center.
Clinical Interests
Pre-clinical validation of anti-angiogenic agents for use in the treatment of retinopathies, cancer and pulmonary disease.
Research Interests
Molecular mechanisms involved in normal development and in disease states using in vitro (cellular and solution biochemistry and structural biology) and in vivo (mouse models) strategies; developing novel therapeutic strategies via structure-aided drug design coupled with in vitro validation and in vivo pre-clinical studies.
Academic Affiliation
Professor, UC Department of Pediatrics
Research Divisions
Developmental Biology
研究兴趣
论文共 85 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nature Communicationsno. 1 (2024): 1-17
Yuhua Wang,Ram Naresh Pandey,Stephen Riffle, Hemabindu Chintala, Kathryn A. Wikenheiser-Brokamp,Rashmi S. Hegde
crossref(2023)
Journal of experimental & clinical cancer research : CRno. 1 (2023): 1-12
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 8 (2021): 3925
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn